Please login to the form below

Tyverb

This page shows the latest Tyverb news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s first-in-class breast cancer therapy wins EU licence

A number of metastatic breast cancer treatments have been rejected by the UK cost-effectiveness watchdog over the last few years, including GlaxoSmithKline's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab),

Latest news

Oncology directions

For advanced breast cancer, Novartis's newly acquired breast cancer drug Tyverb (lapatinib) scores five, but there are four drugs that score three or less, including Eisai's breast cancer medicine
Novartis and GSK complete oncology and vaccines swap

Details of the asset swap were first revealed last April. Novartis claims ownership of several marketed products - including kidney cancer therapy Votrient (pazopanib) and Tyverb (lapatinib) for breast cancer - and also
England's Cancer Drugs Fund: Fixing a broken system

eribulin), GSK's Tyverb (lapatinib) and Novartis' Afinitor (everolimus)), were to be de-listed. ... GlaxoSmithKline's Tyverb (lapatinib):. treatment of advanced breast cancer. GlaxoSmithKline's Arzerra (ofatumumab):.
Pharma condemns Cancer Drugs Fund cuts

GSK. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib). Breast cancer. Votrient (pazopanib).
NHS names drugs to be re-evaluated for Cancer Drugs Fund

Chronic lymphocytic leukaemia. GlaxoSmithKline. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib).

More from news
Approximately 3 fully matching, plus 35 partially matching documents found.

Latest appointments

GSK's oncology president joins NuCana board

During this time he has worked on major cancer products, such as Tykerb/Tyverb and Mekinist.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editor – Medical Education Agency – Bucks: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Manager – Med Comms – Kent: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editorial Director – Medical Education – Oxford: Negotiable

Account Manager – Med Comms – London: Salary TBC

Senior Medical Writer: Great salary and benefits

Senior Medical Writer: Great salary and bebefits

Senior Account Manager / Account Director: Great salary and bebefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Scientific Director: Great salary and bebefits

Senior Account Manager or AD - Medical Communications: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Programme Executive: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

The Holy Grail of HCP Access: This is the data you need to gain access....
No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....